CHENGDU, China , July 2, 2018 /PRNewswire/ -- Sanofi (EURONEXT:
SAN) (NYSE: SNY) is launching a Global R&D Operations Hub with a specialized focus on digitalization and big data analysis in
Chengdu, Sichuan province, China. The new R&D operations hub confirms China as the third pillar of
Sanofi Global Clinical Sciences and Operations, joining facilities in France and the United States.
With an investment of €66 million, the Hub will support the clinical research and development of Sanofi's innovative
drugs by focusing on the management of global multi-center clinical trials data and files. Bringing together global data and
analysis, the Hub will accelerate the availability of trial results, from Phase I to Phase IV. The Hub will take advantage of
local talents to further strengthen Sanofi's digital capabilities.
"Through this new Hub, we will take full advantage of our global experience and R&D
capabilities together with local scientific research strengths to further improve innovation," said
Zhang Ji, Ph.D., Senior Vice President, Global Head of Sanofi R&D Operations. "Our
goal is to link China's innovative achievements with the global ecosystem and develop innovative
drugs in China that could benefit patients around the world."
The Chengdu Hub will target diseases that affect millions of people across our therapeutic areas: diabetes and
cardiovascular diseases, vaccines, oncology, immunology and inflammation, rare diseases, multiple sclerosis and neurology. It
will leverage global cutting-edge biological technology for polypeptides, gene therapy, monoclonal antibodies and multi-specific
antibodies. The Hub plans to recruit 300 local pharmaceutical research and development professionals by 2020.
About Sanofi China
Sanofi China, established in 1982 with headquarters in Shanghai, has a wide range of
businesses covering pharmaceuticals and human vaccines (Sanofi Pasteur). The group has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Fuzhou and Urumqi, and three production bases in Beijing, Hangzhou, and Shenzhen. At the end of 2017, Sanofi had over 9,500 employees
in China.
With the China R&D Center and the Asia-Pacific R&D Center in Shanghai, Sanofi
possesses an overall R&D capability, from drug targets to clinical trials, and has been focusing on frequently occurring
diseases like liver diseases, diabetes, cancers and cardiovascular diseases in China and the
Asia-Pacific region.
Please visit www.sanofi.cn
for more information.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the
few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
Media Relations Contact
Ashleigh Koss
Tel.: 908-981-8745
mr@sanofi.com
|
|
|
Investor Relations Contact
George Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
|
View original content with multimedia:http://www.prnewswire.com/news-releases/sanofi-to-further-accelerate-its-scientific-presence-with-the-opening-of-a-global-rd-operations-hub-in-chengdu-china-300675107.html
SOURCE Sanofi